During the corresponding time, Immuron Limited recorded a revenue increase by 55.99 % year on year, While revenue at the Immuron Limited's corporate clients
Immuron Limited's Comment on Sales, Marketing and Customers
The company provides products for the medical and pharmaceutical markets, focusing on symptoms related to Irritable Bowel Syndrome (IBS) and infectious digestive tract disorders. Its product ProIBS®, a European certified medical device, has been available in the Swedish pharmacy market for over ten years and was launched in Australia in October 2025. ProIBS® is an over-the-counter product indicated for relief of medically diagnosed IBS symptoms. The company also markets Travelan®, a hyperimmune product, in Australia, the United States, and Canada. Revenue is generated from sales of hyperimmune products, including Travelan® and ProIBS®, in these regions. The company is developing therapeutics for anti-infective needs, such as treatments for travelers’ diarrhea and recurrent Clostridioides difficile infections, and seeks to expand its product pipeline through collaborations, including with the U.S. Department of Defense. Its market segments include pharmacy markets in Sweden and Australia, as well as broader markets in the U.S., Canada, and other international regions for Travelan® sales.
Building Bridges: Immuron Partners with InvestorHub to Revolutionize Investor Engagement Melbourne, Australia - August 26, 2025 In a strategic move poised to redefine investor relations, Immuron Limited, the biopharmaceutical company known for its innovative approaches in immune health, has announced its new collaboration with InvestorHub. Immuron, listed on both the Australian Securities Exchange (ASX: IMC) and NASDAQ (IMRN), is taking a bold step forward by embracing digital transformation, aiming to fortify its investor engagement capabilities.InvestorHub, a trailblazer in direct-to-investor engagement, offers a suite of digital tools designed to facilitate more interactive and meaningful communicatio...
Immuron Limited’s Comment on Sales, Marketing and Customers
The company provides products for the medical and pharmaceutical markets, focusing on symptoms related to Irritable Bowel Syndrome (IBS) and infectious digestive tract disorders. Its product ProIBS®, a European certified medical device, has been available in the Swedish pharmacy market for over ten years and was launched in Australia in October 2025. ProIBS® is an over-the-counter product indicated for relief of medically diagnosed IBS symptoms. The company also markets Travelan®, a hyperimmune product, in Australia, the United States, and Canada. Revenue is generated from sales of hyperimmune products, including Travelan® and ProIBS®, in these regions. The company is developing therapeutics for anti-infective needs, such as treatments for travelers’ diarrhea and recurrent Clostridioides difficile infections, and seeks to expand its product pipeline through collaborations, including with the U.S. Department of Defense. Its market segments include pharmacy markets in Sweden and Australia, as well as broader markets in the U.S., Canada, and other international regions for Travelan® sales.
Sources:
Immuron Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Immuron Limited’s corporate clients.
For your research, we’ve provided 9 tables on Immuron Limited corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
113.05 %